Considerable Health Care System Burden for Undiagnosed COPD

Share this content:
Considerable Health Care System Burden for Undiagnosed COPD
Considerable Health Care System Burden for Undiagnosed COPD

FRIDAY, Aug. 12, 2016 (HealthDay News) -- The overall health system burden of exacerbations in patients with undiagnosed chronic obstructive pulmonary disease (COPD) is considerable, according to a study published in the Aug. 1 issue of the American Journal of Respiratory and Critical Care Medicine.

Laura E. Labonte, from McGill University Health Centre in Canada, and colleagues compared exacerbation-like respiratory events, event prevalence, and the odds of using medication and/or health services in subjects with diagnosed and undiagnosed COPD who were participating in the CanCOLD (Canadian Cohort Obstructive Lung Disease) study.

The researchers found that there were 355 subjects with undiagnosed and 150 with diagnosed COPD. Those with undiagnosed disease were less symptomatic and had less functional impairment; they also had been prescribed fewer respiratory medications and had better health status. Diagnosed subjects had a higher incidence of reported exacerbation-like events. Severity of airflow obstruction was tied to incidence of exacerbation-like events in both groups. Though patients with diagnosed disease were more frequently prescribed medication for exacerbations, health service use for exacerbation events was similar in the two groups.

"Although patients with undiagnosed COPD experience fewer exacerbations than those with diagnosed COPD, they use a similar amount of health services for exacerbation events; thus, the overall health system burden of exacerbations in those with undiagnosed COPD is considerable," the authors write.

Several authors disclosed financial ties to the pharmaceutical industry, and the CanCOLD study receives funding from pharmaceutical companies.

Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Approves Zejula for Certain Female Cancers

FDA Approves Zejula for Certain Female Cancers

PARP inhibitor may help fight tumors affecting the ovaries, fallopian tubes, or peritoneum

USPSTF: Evidence Lacking for Celiac Dz Screen in Asymptomatic

USPSTF: Evidence Lacking for Celiac Dz Screen in ...

Insufficient evidence for weighing benefits, harms of screening for celiac disease in asymptomatic

Lap, Abdominal Hysterectomy Equal for Early Endometrial CA

Lap, Abdominal Hysterectomy Equal for Early Endometrial CA

Equivalent disease-free survival at 4.5 years for stage I endometrial cancer with TAH, TLH

is free, fast, and customized just for you!

Already a member?

Sign In Now »